Key statistics
On Thursday, Summit Therapeutics Inc (SMMT:NMQ) closed at 18.42, -45.65% below its 52-week high of 33.89, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.74 |
---|---|
High | 19.14 |
Low | 18.03 |
Bid | 18.50 |
Offer | 18.75 |
Previous close | 18.62 |
Average volume | 1.82m |
---|---|
Shares outstanding | 737.45m |
Free float | 115.30m |
P/E (TTM) | -- |
Market cap | 13.58bn USD |
EPS (TTM) | -0.2768 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
- PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
- Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
- Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
- PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
- Summit Therapeutics Raises $235 Million
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
More ▼